Navigation Links
Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting
Date:4/14/2009

-- Phase 1 Data from Colorectal Cancer and Oral Picoplatin Trials To Be Presented --

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present final data from two Phase 1 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the American Association for Cancer Research 100th Annual Meeting 2009 at the Colorado Convention Center in Denver. The Company will present efficacy and safety data from its Phase 1 trial of picoplatin in colorectal cancer (CRC) and bioavailability data from its Phase 1 trial of an oral formulation of picoplatin.

    Details are as follows:

    A Phase 1 study of picoplatin in combination with 5-fluorouracil and
    leucovorin (FOLPI) for colorectal cancer (CRC): Comparison of two
    picoplatin schedules
    Abstract #3578
    Earhart R, Gladkov OA, Cheporov SV, Biakhov MY, Manikhas B, Berdov B,
    Tjulandin S, Breitz H, De Jager R.
    Tuesday, April 21, 8:00 a.m. MDT
    Clinical Research 11 Session
    Hall B-F, Poster Section 30

    A Phase 1 randomized crossover oral picoplatin bioavailability
    pharmacokinetics and pharmacodynamics study
    Abstract #3594
    Phillips A, Saleh M, Yee L, Sharma S, Houston S, Karlin D, Breitz H,
    DeJager R, Earhart R.
    Tuesday, April 21, 8:00 a.m. MDT
    Clinical Research 12
    Hall B-F, Poster Section 31

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic 2 colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit

http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... MA (PRWEB) , ... March 23, 2017 , ... ... “a viscoelastic material that exhibits both viscous and elastic characteristics when deformed, which ... disc polymer exhibits properties to gently absorb compressive forces and return to its ...
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
(Date:3/23/2017)... In today,s pre-market research, Stock-Callers.com ... Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate Pharmaceuticals ... and Regulus Therapeutics Inc. (NASDAQ: RGLS ). ... its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn more ... ...
Breaking Biology Technology:
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/28/2017)... 27. Februar 2017  EyeLock LLC, ein marktführendes Unternehmen ... erstklassige biometrische Lösung zur Iris-Erkennung auf der ... LTE auf dem Mobile World Congress 2017 ... in Halle 3, Stand 3E10, vorstellen. ... Qualcomm Haven™ – eine Kombination aus Hardware, ...
Breaking Biology News(10 mins):